We recently reported that bezafibrate, a lipid-lowering drug of the fibrate class, administered in addition to clomiphene citrate (CC) successfully induced ovulation in CC-resistant polycystic ovary syndrome (PCOS) patients. We hypothesized that bezafibrate may directly affect ovarian follicle development. Insulin resistance and compensatory hyperinsulinemia are important for the pathogenesis of PCOS. In this study, we first examined the effects of tumor necrosis factor-alpha (TNF), which plays a role in insulin resistance, on follicle development by using the follicle culture system. TNF significantly inhibited follicle-stimulating hormone (FSH)-induced follicle development, 17beta-estradiol (E2) secretion, and ovulation rate in a dose-dependent manner. We then examined whether bezafibrate treatment could rescue the inhibition of FSH-induced follicle development and steroidogenesis by TNF. Bezafibrate treatment rescued inhibition of follicle development, secretion of E2, and ovulation rate by TNF. We examined the expression of peroxisome proliferator-activated receptor (PPAR) subtypes in mouse preantral follicles. As the protein expression of only PPARG was observed in mouse preantral follicles, we examined whether bezafibrate could affect follicle development and steroidogenesis through PPARG pathways. Treatment with GW1929, a selective PPARG agonist, restored inhibition of FSH-induced follicle development and steroidogenesis by TNF, whereas treatment with GW9662, a selective PPARG antagonist, canceled the restorative effects of bezafibrate. Collectively, the results in this study suggest that bezafibrate may directly exhibit a restorative effect on the inhibition of ovarian follicle development and steroidogenesis by TNF through the PPARG pathway.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common ovulatory disorder in reproduction age women and affects 5%-10% of the population, accounting for more than 75% of cases of anovulatory infertility [1, 2] . Although the cause of PCOS remains unknown, insulin resistance and compensatory hyperinsulinemia are important for the pathogenesis of ovulatory dysfunction in PCOS patients. Insulin resistance with compensatory hyperinsulinemia is observed in approximately 70% of PCOS women [3, 4] . Hyperinsulinemia directly contributes to an increase in androgen biosynthesis in the ovary [5] and to a decrease in the level of hepatic sex hormonebinding globulin, resulting in an elevated level of free androgen [6] . Moreover, hyperinsulinemia inhibits hepatic secretion of insulin-like growth factor binding protein (IGFBP), resulting in activation of IGF bioavailability and an increase in androgen production from theca cells [7] .
Hyperinsulinemia may also increase luteinizing hormone secretion, resulting in excessive ovarian androgen synthesis [3] . Intraovarian hyperandrogenism suppresses aromatase activity and 17b-estradiol (E2) production in granulosa cells [8, 9] and consequently results in inhibiting granulosa cell proliferation and arresting antral follicular development.
The characteristic morphological feature of polycystic ovaries in anovulatory women is the accumulation of antral follicles 2-9 mm in diameter [10] . In other words, there is an apparent failure to select a dominant follicle [10] . Serum follicle-stimulating hormone (FSH) concentration is suppressed below the threshold level required during early follicular phase to stimulate normal follicle development [11] . Indeed, clomiphene citrate (CC) or exogenous FSH results in successful follicle growth in PCOS women, indicating that abnormal antral follicle development may occur in the ovary of PCOS women. In addition to the abnormal late phase of follicle development, several studies report that the early phase of follicle development is also impaired in ovaries of PCOS patients [12, 13] . Webber et al. [14] reported that the total number of preantral follicles in the polycystic ovary is significantly higher than in the normal ovary. Moreover, while the proportion of primordial follicles is decreased, that of growing primary follicles is higher in the polycystic ovary than in the normal ovary [14] . Collectively, development of both preantral and antral follicles might be impaired in the polycystic ovary; however, the molecules involved in abnormal follicle development in the polycystic ovary remain unknown. It is a critical problem that suitable animal models are not available for understanding follicle development that mimics PCOS in humans.
It has been reported that levels of adipocytokines, such as tumor necrosis factor-a (TNF), resistin, free fatty acid, and interleukin 6, which raise insulin resistance [15, 16] , are higher in obese and nonobese PCOS women than those in weightmatched non-PCOS control women [17, 18] . TNF is a well-known adipocytokine that is capable of inducing apoptosis in diverse types of cells [19] . Several studies report that TNF is critically involved in the apoptosis of preantral and antral follicles in mouse and human ovaries [20, 21] . Moreover, TNF affects ovarian steroidogenesis in granulosa cells in in vitro culture [22, 23] .
In vitro mouse follicle culture studies provide important information for understanding early and late stages of folliculogenesis [24, 25] . Androgen treatment of late preantral and antral follicles impaired follicle development, whereas it promoted follicle development in early preantral follicles in an in vitro mouse follicle culture experiment [26] . So far, there have been no data indicating whether adipocytokines, which are implicated in the pathogenesis of PCOS, affect follicle development by using an in vitro mouse follicle culture system; therefore, we first examined the effects of TNF on follicle development and steroidogenesis by using an in vitro mouse preantral follicle culture system.
We recently reported that bezafibrate, a lipid-lowering fibrate class drug, administered in addition to CC successfully induced ovulation in CC-resistant PCOS patients with dyslipidemia [27] . Bezafibrate, a fibric acid derivative, is a nonselective ligand for peroxisome proliferator-activated receptors (PPAR), such as PPAR-a (PPARA), PPAR-d (PPARD), and PPAR-c (PPARG) [28, 29] . As the mRNAs of PPARA, PPARD, and PPARG are expressed in the ovary [30, 31] , these PPARs are considered to be involved in ovarian follicle development and steroidogenesis [32, 33] . We hypothesized that bezafibrate may directly affect ovarian follicle development through PPARs. In this study, we also examined the restorative effect of bezafibrate on the inhibition of FSH-induced follicle development and steroidogenesis by TNF in an in vitro follicle culture system.
MATERIALS AND METHODS

Animals
This study was performed with permission from the Committee of Animal Experimentation, Yamagata University Faculty of Medicine. Mature female ICR mice older than 6 wk of age were used in this study. They were housed at 238C-258C on a 12L:12D cycle (lights-on, 0700-1900 h) and fed pellet food and water ad libitum.
Reagents
Human pituitary FSH (catalog no. F4021), bezafibrate (catalog no. B7273), human TNF (catalog no. T6674), GW1929 (catalog no. G5668), and GW9662 (catalog no. M6191) were purchased from Sigma Chemical Co. (St. Louis, MO). Anti-PPARA antibody (catalog no. sc-9000), anti-PPARD antibody (catalog no. sc-74517), Hep G2 cell lysate (positive control for PPARA; catalog no. sc-2227), Jurkat nuclear extract (positive control for PPARD; catalog no. sc-2132), and anti-a-tubulin antibody (catalog no. sc-5286) for Western blotting were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-PPARG antibody for Western blotting was obtained from Cell Signaling Technology (catalog no. 2443; Beverly, MA). Other reagents were obtained from Sigma unless otherwise indicated.
Collection of Preantral Follicles
Mature female mice were killed by cervical dislocation, and early preantral follicles were mechanically isolated from ovaries by using a 30-gauge needle under a stereomicroscope. The collected preantral follicles were pooled in a solution of HEPES-minimal essential medium (HEPES-MEM; catalog no. 12360038; Invitrogen Corp., Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS; catalog no. 12603c; JRH bioscience, Lenexa, KS). After follicles were washed twice with HEPES-MEM, follicles with the following characteristics were selected: 1) a diameter of 120-150 lm, 2) an immature oocyte centrally located within the follicle, 3) an intact basal membrane, and 4) surrounded by theca cells [26] . Selected follicles corresponded to type 3b follicles in Pedersen and Peter's classification [34] . These procedures were performed at 378C.
In Vitro Preantral Follicle Culture
Follicle culture medium consisted of a-MEM GlutaMax (catalog no. 32561037; Invitrogen Corp.) supplemented with 5% FBS, 100 units/ml penicillin, and 100 lg/ml streptomycin, 5 lg/ml insulin, 5 lg/ml transferrin, and 5 ng/ml selenium (Invitrogen Corp.). The medium was sterilized with a 20-lm-pore filter after the addition of supplements. This was the basal medium and was used as a control. As FSH treatment at 100 mIU/ml was the minimum effective concentration for developing follicles (data not shown), 100 mIU/ml FSH was added to the basal medium in the in vitro follicle culture system. Each follicle was individually cultured to one follicle per well in a 24-well plate (Falcon; Becton Dickinson Labware, Franklin Lakes, NJ) containing 1 ml of culture medium at 378C with 5% CO 2 in air. Follicles were cultured for 13 days. Follicular growth was monitored every 2 days (Days 2, 4, 6, 8, 10, and 12 of culture) with an inverted microscope at 3200 magnification. Each follicle image was captured by a cooled charge-coupled device camera system (DP-50; Olympus, Tokyo, Japan), and follicle diameters were measured using Image J version 1.43 software imaging system (National Institutes of Health, Bethesda, MD). A total of 500 ll of conditioned medium was refreshed with preincubated medium every 2 days (Days 2, 4, 6, 8, 10, and 12). Spent medium collected on the indicated days was pooled per culture plate and frozen at À808C for later determination of E2. When follicles clearly formed an antral-like cavity on Day 12, ovulation and meiotic resumption were induced by refreshing medium with culture medium supplemented with 5 IU/ml human chorionic gonadotropin (hCG; Mochida Pharmaceutical Co., Tokyo, Japan). On Day 13, follicles were checked for ovulation 16 h after hCG administration and were considered to be ovulating when they were visibly ruptured and the cumulus oocyte complex (COC) was extruded from the follicles (Fig. 1A) . Ovulated COCs were evaluated for cumulus expansion (Fig. 1C) and germinal vesicle breakdown (GVBD), indicating meiotic resumption of oocytes, after the surrounding cumulus cells were removed by repeated pipetting in the presence of 300 IU/ml hyaluronidase.
Assessment of Follicle Survival
Using the method reported by Adriaenssens et al. [35] and Lenie et al. [36] , we assessed follicle morphology and classified the follicular development stage as follicular, diffuse, or antral in the in vitro preantral follicle culture. Briefly, the follicular stage of the follicle is characterized by preservation of the basal membrane of the follicle. Initially, theca cells grow out to the culture plate, and granulosa cell proliferation is limited. Follicles remain in this stage until Day 4 of culture. The diffuse stage of the follicle is characterized by marked granulosa cell proliferation and a large preantral follicle. From Day 4 to Day 6 of culture, granulosa cells overgrow the theca cell monolayer through the basement membrane, and the follicles enlarge gradually. The antral stage of the follicle is characterized by the presence of an antral-like cavity (Fig. 1B) . From Day 6 or Day 8 up to Day 12 of culture, granulosa cells differentiate into two spatially and functionally distinct populations, cumulus cells and mural granulosa cells, and the follicles form an antral-like cavity.
In this culture system, follicle survival was defined as follicles that retained their oocyte completely embedded within the granulosa cell mass and exhibited no signs of degeneration [36, 37] . Follicle degeneration was characterized by failure of the granulosa cells to multiply or release oocytes or by collapse (Fig.  1A ) [36] .
Experimental Conditions and Evaluation Parameters
In this experiment, we used the condition under which culture was treated with FSH alone (in the presence or absence of vehicle) as a positive control or was treated without FSH and another compound (in the presence or absence of vehicle) as a negative control. All compounds were added to culture medium during the in vitro culture period. TNF was dissolved in distilled water at 10 lg/ ml and stored at À808C until used. Selection of the TNF concentration used in this experiment followed that reported in the literature concerning effects of TNF on ovary and granulosa cells in an in vitro culture [38] [39] [40] . Bezafibrate, GW1929, and GW9662 were dissolved in dimethyl sulfoxide (DMSO) at 400 mM, 20 mM, and 200 lM, respectively, and were stocked at À808C until used. The final concentration of DMSO in the medium never exceeded 0.1%. In the preliminary study, we tested the effects of DMSO as a vehicle on follicle development. There were no significant differences in follicle development between the groups treated with and without DMSO (data not shown).
Effects of various treatments on follicle development and steroidogenesis were evaluated as follicle survival, antral-like cavity formation, increased follicle diameter, and measurement of E2 concentration in the culture medium.
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Moreover, the effects of various treatments on ovulation and GVBD, indicating resumption of meiosis, were evaluated.
17b-Estradiol Measurement
Medium cultured with individual mouse follicles was replaced every other day, and the collected medium was pooled and stored at À808C until E2 levels were measured. Levels of E2 in the collected culture medium were measured using the estradiol enzyme immunoassay kit (catalog no. 582251; Cayman Chemical Co., Ann Arbor, MI) according to the manufacturer's protocol. Culture medium from nonsurviving follicles was excluded from the experiment.
RNA Isolation and RT-PCR
One hundred preantral follicles were collected from mouse ovaries. Total RNA was isolated from mouse tissues and follicles using the RNeasy mini-kit (Qiagen, Inc., Valencia, CA). Total RNA (up to 5 lg) was converted to complementary DNA with a first-strand cDNA synthesis kit according to the manufacturer's instructions (SuperScript first-strand synthesis system for RT-PCR; Invitrogen). An aliquot (1 lg) of synthesized cDNA was used for PCR amplification in a total volume of 50 ll. PCR primer sets used for mouse PPAR-a (Ppara), PPAR-d (Ppard), PPAR-c (Pparg), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH [Gapdh]) cDNA amplification were FIG. 1. An in vitro mouse preantral follicle culture system and the effects of FSH on follicle development and E2 production are shown. Follicles were cultured with or without 100 mIU/ml FSH for up to 12 days. After 12 days of culture, hCG (5 IU/ml) was added to the culture medium to induce ovulation. Follicles were evaluated for morphology, and follicle diameter was measured every other day. Medium was refreshed every other day, and E2 concentrations in the collected medium were measured. A) Examples of follicular growth treated with or without FSH during in vitro culture are shown. When follicles were cultured without FSH (control), almost no follicles survived or showed signs of degeneration, did not grow in a multilayered pattern (a), or the oocyte (black arrowhead) was separated from granulosa cells (white arrowhead) (b), or a follicle shrank (c). FSH treatment induced follicle growth and antral-like cavity formation at 12 days of culture (d). After 16 h of hCG treatment, the COC was visibly extruded from the cultured follicle. Double arrowheads show ovulated COCs (e). Bar ¼ 100 lm. B) High magnification of the follicle shows antral-like cavity formation. Bar ¼ 100 lm. C) High magnification of ovulated COC is shown. Arrowhead shows the oocyte. Bar ¼ 100 lm. D) Time courses of follicle growth by the follicle diameter in control and FSH-treated groups during in vitro culture are shown. *P , 0.05. E) Time courses of E2 concentration in control and FSH-treated groups during the in vitro culture are shown. *P , 0.05.
forward 5
0 -ACGATGCTGTCCTCCTTGATG-3 0 and reverse 5 0 -GTGTGAT AAAGCCATTGCCGT-3 0 primers for Ppara (GenBank accession number NM_011144); forward 5 0 -GCTGCTGCAGAAGATGGCA-3 0 and reverse 5 0 -CACTGCATCATCTGGGCATG-3 0 primers for Ppard (GenBank accession number NM_011145); forward 5 0 -TTCAGAAGTGCCTTGCTGTG-3 0 and reverse 5 0 -TCTTTCCTGTCAAGATCGCC-3 0 primers for Pparg (GenBank accession number NM_001127330); and forward 5 0 -ACCACAGTCCATGC CATCAC-3 0 and reverse 5 0 -TCCACCACCCTGTTGCTGTA-3 0 primers for Gapdh (GenBank accession number NM_002046). The thermal cycle profile used for PPARA, PPARD, and GAPDH was 40 cycles of denaturation at 948C for 15 sec, annealing at 628C for 40 sec, and extension at 728C for 45 sec. The profile for PPARG was 25 cycles of denaturation at 948C for 30 sec, annealing at 558C for 30 sec, and extension at 688C for 30 sec. PCR products were analyzed by electrophoresis using 1.5% agarose gels stained with ethidium bromide.
Immunoblot Analysis
Immunoblot analysis was as described previously [41] . Briefly, 100 preantral follicles were collected from mouse ovaries and lysed in SDS sample buffer (100 mM Tris-HCl [pH 6.8], 4% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.01% bromophenol blue). Samples were separated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked in a 13 solution of Tris-buffered saline-Tween buffer containing 10% skimmed milk powder for 1 h. Membranes were then washed and incubated overnight with primary antibodies to PPARA (1:1000 dilution), PPARD (1:1000 dilution), PPARG (1:1000 dilution), and a-tubulin (1:1000 dilution) and then incubated with the corresponding secondary horseradish-peroxidaseconjugated immunoglobulin G for 1 h. Immunoreacted bands were visualized using the enhanced chemiluminescence Western blotting system.
Statistical Analysis
All experiments consisted of at least five independent experimental runs. Differences between means were calculated by one-way ANOVA, followed by a post hoc test, and data, expressed as percentages, were analyzed by the Fisher exact probability test, using GraphPad Prism version 5.0 software for Windows (GraphPad Software Inc., San Diego, CA; Microsoft, Bellevue, WA). Values are given as means 6 SEM. Significant difference was defined as a P value of ,0.05.
RESULTS
FSH-Induced Follicle Development and Steroidogenesis in an In Vitro Culture
In vitro mouse ovarian culture methods provide a useful tool for studying follicle development. We used an in vitro mouse ovarian follicle culture system for up to 12 days to study the effects of various compounds on FSH-induced follicle development and steroidogenesis (Fig. 1) . FSH treatment significantly induced follicle growth and E2 secretion into culture medium compared with no FSH treatment (control) (Fig. 1) . Although most follicles in the control group disintegrated and degenerated within 10 days of culture, follicles cultured with FSH grew larger and formed a large antral-like cavity at 12 days of culture (Fig. 1, A and B ). Follicle survival rates at 12 days of culture in the control and FSH-treated groups were 6% and 63%, respectively (Fig. 2B) . Moreover, although the antral-like cavity formation rate at 12 days of culture in the control group was 0%, it was 63% in the FSH-treated group (Fig. 2D) . Although ovulation was never observed in the control group, 79% of follicles with an antrallike cavity exhibited ovulation after stimulation by hCG in the FSH-treated group (Table 1 ). All ovulated COCs had mucification with expansion of cumulus cells (Fig. 1C) , and all their oocytes underwent GVBD (Table 1) . Diameters of follicles treated with FSH were significantly increased at 4 days of culture compared with those of control follicles (Fig. 1D) . Concentration of E2 in medium was significantly increased in the FSH-treated group at 4 days of culture compared with that of the control group (Fig. 1E) .
Effects of TNF on In Vitro Follicle Development and Steroidogenesis
TNF is a cytokine capable of inducing apoptosis in diverse cell types [19] , including follicle development [21] . Several studies report that TNF is critically involved in the apoptosis of preantral and antral follicles [20, 21] . Serum and follicular TNF concentrations are elevated in PCOS patients [17, 18, 42] . Moreover, TNF affects ovarian steroidogenesis in granulosa cells in vitro [22, 23, 40] ; therefore, we examined the effects of TNF on follicle development by using an in vitro mouse follicle culture system. First, we tested the time course and doseresponse relationship between TNF and in vitro follicle development and steroidogenesis. TNF significantly impaired FSH-induced follicle growth and steroidogenesis in a time-and dose-dependent manner (Fig. 2) . Although TNF treatments at concentrations of 2, 5, and 10 ng/ml did not affect follicle survival until 8 days of culture in the FSH-treated group, they accelerated follicle death from 10 days of culture ( Fig. 2A) . TNF significantly inhibited follicle survival from 12 days of culture in the FSH-treated group in a dose-dependent manner (Fig. 2B) . TNF treatment at concentrations of 2, 5, and 10 ng/ml delayed and decreased antral-like cavity formation in the FSH-treated group from 6 days of culture (Fig. 2C ) and significantly inhibited antral-like cavity formation from 12 days of culture in the FSH-treated group, in a dose-dependent manner (Fig. 2D) . Although TNF at 2 ng/ml did not affect follicle diameter, TNF at 5 and 10 ng/ml significantly decreased follicle diameter at 12 days of culture in the FSH-treated group (Fig. 2E) . At concentrations of 2, 5, and 10 ng/ml, TNF significantly decreased FSH-induced E2 production in a dose-dependent manner (Fig. 2F) . Moreover, we examined the effects of TNF on ovulation and meiotic resumption of oocytes in the FSH-treated group (Table 1) . TNF at concentrations of 2, 5, and 10 ng/ml significantly decreased ovulation induced by hCG in the FSHtreated group in a dose-dependent manner (Table 1 ). All ovulated COCs in the TNF-treated (2, 5, and 10 ng/ml) groups showed cumulus expansion (data not shown). The percentage of GVBD of ovulated COCs by TNF at concentrations of 2, 5, and 10 ng/ml was 100% (Table 1) . Although TNF impaired ovulation induced by hCG in the FSH-treated group, it did not affect meiotic resumption of oocytes. As TNF at 5 ng/ml was the minimum concentration that inhibited FSH-induced follicle development and steroidogenesis in in vitro culture, we used the concentration of 5 ng/ml TNF in the following experiments.
Bezafibrate Rescued TNF Inhibition of FSH-Induced Follicle Development and Steroidogenesis
Next, we examined whether bezafibrate could rescue the inhibition by TNF of FSH-induced follicle development and steroidogenesis. Preliminary experiments showed that 200 lM was the minimum effective concentration of bezafibrate necessary to restore the inhibition of FSH-induced follicle development and steroidogenesis by TNF (5 ng/ml) (data not shown). Then, we used bezafibrate at a concentration of 200 lM in the following experiment. Bezafibrate significantly restored inhibition by TNF of FSH-induced follicle development and steroidogenesis (Fig. 3) . Although TNF inhibited follicle survival in the FSH-treated group from 10 days of culture, bezafibrate rescued the follicles (Fig. 3A) . Bezafibrate completely restored the inhibition by TNF of FSH-induced follicle survival at 12 days of culture (Fig. 3B) . Whereas TNF inhibited and delayed antral-like cavity formation in the FSHtreated group from 6 days of culture, bezafibrate rescued it (Fig. 3C) . Bezafibrate significantly restored the inhibition by 898 TNF of FSH-induced antral-like cavity formation at 12 days of culture (Fig. 3D) . Bezafibrate did not restore the inhibition by TNF of the FSH-induced increase in follicle diameter at 12 days of culture (Fig. 3E) , while bezafibrate significantly, but partly, restored the inhibition by TNF of FSH-induced E2 production (Fig. 3F) . Moreover, we examined the effects of bezafibrate on the inhibition by TNF of the ovulation and meiotic resumption of oocytes induced by hCG with or without FSH treatment (Table 2) . Bezafibrate partly but significantly restored the inhibition by TNF of the ovulation rate per total tested follicles in the FSH-treated group (Table 2) ; however, bezafibrate did not significantly restore the inhibition by TNF of the ovulation rate of follicles with antral-like cavity formation in the FSH-treated group (Table 2 ). All oocytes underwent GVBD when COCs were ovulated in the FSHtreated group. 
Expression of PPAR Subtypes in Mouse Preantral Follicles
Because bezafibrate is a nonselective PPAR agonist, bezafibrate could act through any PPAR subtype, PPARA, PPARD, or PPARG; therefore, we examined which PPAR subtypes were expressed in preantral follicles. Whereas mRNA expression levels of PPARA and PPARG were detected by RT-PCR (Fig. 4A) , the protein expression of only PPARG was observed in preantral follicles (Fig. 4B) . Whereas PPARG2 was expressed in mouse adipose tissue [43] , PPARG1 was expressed in the preantral follicles; therefore, it was speculated that PPARG may play an important role in preantral follicle growth.
PPARG Selective Agonist Rescued the Inhibition by TNF of FSH-Induced Follicle Development and Steroidogenesis
We next explored whether a selective PPARG agonist could rescue the inhibition by TNF of FSH-induced follicle growth and steroidogenesis. Preliminary experiments showed that 10 lM GW1929, a selective PPARG agonist, was the minimum effective concentration required to restore the inhibition of FSH-induced follicle development and steroidogenesis by 5 ng/ ml TNF (data not shown). Then, we applied GW1929 at a concentration of 10 lM in the following experiment. GW1929 restored the inhibition by TNF of FSH-induced follicle development and steroidogenesis (Fig. 5) . GW1929 completely restored the inhibition by TNF of follicle survival and antrallike cavity formation at 12 days of culture (Fig. 5, A and B) . GW1929 did not restore the inhibition by TNF of the FSHinduced increase in follicle diameter at 12 days of culture (Fig.  5C ), while GW1929 partly but significantly restored the inhibition by TNF of FSH-induced E2 production (Fig. 5D) . Moreover, we examined the effects of GW1929 on the inhibition by TNF of the ovulation and meiotic resumption induced by hCG with or without FSH treatment (Table 3) . GW1929 partly but significantly restored the inhibition by TNF 
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of the ovulation rate in all tested follicles in the FSH-treated group (Table 3) ; however, GW1929 did not significantly restore the inhibition by TNF of the ovulation rate of follicles with antral-like cavity formation in the FSH-treated group. All oocytes underwent GVBD when COCs ovulated in the treated group (Table 3 ). The restorative effects of GW1929 on the inhibition by TNF were similar to those produced by bezafibrate.
PPARG Selective Antagonist Canceled the Restorative Effects of Bezafibrate on the Inhibition by TNF of FSHInduced Follicle Development and Steroidogenesis
We further examined whether a selective PPARG antagonist could cancel the restorative effects of bezafibrate on the inhibition by TNF of FSH-induced follicle growth and steroidogenesis. Preliminary experiments showed that 10 nM GW9662, a selective PPARG antagonist, was the minimum effective concentration required to cancel the restorative effects of bezafibrate on the inhibition of FSH-induced follicle development and steroidogenesis by 5 ng/ml TNF (data not shown). Then, we applied GW9662 at a concentration of 10 nM in the following experiment. Bezafibrate restored the inhibition by TNF of follicle survival and antral-like cavity formation at 12 days of culture, whereas GW9662 completely canceled these restorative effects by bezafibrate (Fig. 6, A and  B) . GW9662 treatment did not affect the inhibition by TNF of FSH-induced increase in follicle diameter at 12 days of culture (Fig. 6C) , while GW9662 significantly abolished the restorative effect of bezafibrate on the inhibition by TNF of FSHinduced E2 production (Fig. 6D) . Moreover, we examined the effects of GW9662 treatment on the restorative effects of bezafibrate on the inhibition by TNF of the ovulation induced by hCG with or without FSH treatment (Table 4) . Bezafibrate restored the inhibition by TNF of the ovulation rate in all tested follicles in the FSH-treated group, whereas GW9662 canceled the restorative effect of bezafibrate (Table 4) .
DISCUSSION
In this study, we first examined the effects of TNF on FSHinduced follicle development and steroidogenesis by using an in vitro mouse preantral follicle culture system. We found that TNF impaired FSH-induced follicle development, such as   FIG. 4 . Expression of PPAR subtypes in mouse preantral follicles is shown. mRNA (A) and protein (B) expression levels of PPAR subtypes in mouse preantral follicles are shown. Preantral follicles were mechanically isolated from mouse ovaries. One hundred preantral follicles were collected and subjected to RT-PCR and Western blot analysis. A) Total RNA was isolated from preantral follicles and various mouse tissues: liver, stomach, and adipose tissues. RT-PCR assay was performed to detect mRNA of PPARA (upper panel), PPARD (middle panel), and PPARG (lower panel). Positive controls for PPARA, PPARD, and PPARG were liver, stomach, and adipose tissue, respectively. GAPDH was used as an internal control. B) Protein expression levels of PPARA (upper panel), PPARD (middle panel), and PPARG (lower panel) were examined by Western blot analysis, using respective antibodies. a-Tubulin was used as an internal control. Positive controls for PPARA and PPARD were Hep G2 cell lysate and Jurkat nuclear extract, respectively (see Materials and Methods). Mouse adipose tissue was used as a positive control for PPARG. Experiments were repeated three times with consistent results, and representative results are shown. Presence (þ) or absence (À) of RT in the RT-PCR reaction is shown. P.C., positive control. 
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follicle survival, antral-like cavity formation, granulosa cell proliferation, and E2 production. We also observed that bezafibrate restored the inhibition by TNF of FSH-induced follicle survival and steroidogenesis. Because there are limitations place on the use of human ovaries, in vivo animal models are used for studying follicle development, which is simulated in PCOS. Administration of diethylstilbestrol or several androgens resulted in anovulation and polycystic ovary in rodent animals [44, 45] ; however, follicles from these steroid-treated animals apparently grow normally under in vitro culture conditions [45] . Therefore, these in vivo animal models may not be suitable for studying the mechanism of follicle development in PCOS. The in vitro follicle culture system is a powerful tool for studying preantral and antral follicle development and follicle steroidogenesis [46] [47] [48] .
TNF is a well-known proinflammatory cytokine that is capable of inducing apoptosis in diverse types of cells [19] . TNF has been identified in the ovaries, especially in the follicles, of many species, such as mice [49] , rats [50] , rabbits [51] , and humans [52] . Several studies have reported that TNF is critically involved in the apoptosis of preantral and antral follicles in mouse and human ovaries [20, 21] . Moreover, TNF affects ovarian steroidogenesis in granulosa cells in vitro [22, 23, 40] . In this study, we have shown that TNF treatment impaired FSH-induced follicle development and E2 production in a dose-dependent manner by using an in vitro follicle culture system (Fig. 2) , consistent with previous studies [20] [21] [22] [23] . TNF did not exhibit an inhibitory effect on FSH-induced follicle survival up to 8 days of culture ( Fig. 2A) when apparent antrallike cavity formation was observed (Fig. 2C) . These results suggest that TNF acts mainly on antral but not preantral follicles. TNF can induce both cell death by apoptosis and cell proliferation and exerts its effects by binding to TNF receptor 1 (TNFR1) or TNFR2 [53] . Both subtypes of TNF receptor are expressed in oocytes, granulosa cells, and interstitial cells in neonatal mouse and rat ovaries [39, 54] . TNFR1-deficient mice have phenotypes characterized by early senescence and poor fertility, while TNFR2-deficient mice have no phenotypes of female fertility [55] . Greenfeld et al. [39] reported that TNF treatment resulted in oocyte death and decrease in the number of primary follicles via TNFR2 in neonatal mouse ovaries, using an in vitro ovarian culture system [39] . In the present study, we did not examine which types of TNF receptors were expressed in the preantral and antral follicles. Because the human TNF used in this experiment is a specific agonist for murine TNFR1 but not for TNFR2 [56] , TNF may exert its inhibitory effects on FSH-induced follicle development and steroidogenesis through TNFR1. Further investigations are needed to explore the expression of subtypes of TNF receptors in the follicle and their roles in follicle development.
We recently reported that bezafibrate, a lipid-lowering fibrate drug, administered in addition to CC successfully induced ovulation in CC-resistant PCOS patients with   FIG. 6 . GW9662 canceled the restorative effects of bezafibrate on the inhibition by TNF of FSH-induced follicle development and steroidogenesis. Follicles were cultured with TNF (5 ng/ml) and/or bezafibrate (200 lM) and/or GW9662 (10 lM) in the presence or absence of FSH. Follicles were evaluated for morphology under a microscope, and survival rate and antral-like cavity formation rate were determined. Follicle diameter was measured every other day. Medium cultured with individual follicles was refreshed every other day, and E2 concentrations in the collected medium were measured. A) Follicle survival rates at 12 days of culture with various treatments are shown. Numbers inside bars indicate the number of survived follicles/total tested follicles. B) Antral-like cavity formation rates at 12 days of culture with various treatments are shown. Numbers inside bars indicate the numbers of follicles that formed antral-like cavity/total tested follicles. C) Follicle growth at 12 days of culture with various treatments is shown. Data are shown as means 6 SEM. D) E2 concentrations in medium at 12 days of culture with various treatments are shown. Data are shown as means 6 SEM. All experiments consisted of at least five independent experimental runs. The group treated only with DMSO was used as a control. Bars with different letters represent significant differences (P , 0.05). BEZAFIBRATE REGULATES FOLLICULAR DEVELOPMENT 903 dyslipidemia [27] . The mechanism by which ovulation was restored by bezafibrate remains unknown. Many studies have suggested that insulin-sensitizing drugs, metformin and PPARG agonists, troglitazone, pioglitazone, and rosiglitazone, decrease peripheral insulin resistance [57] [58] [59] [60] . The decrease in insulin levels results in menstrual regularization in PCOS women [59, 60] , which indicates restoration of a normal ovulatory cycle. In fact, bezafibrate therapy has been demonstrated to delay the development of type 2 diabetic mellitus by decreasing insulin resistance [29, 61] . Bezafibrate is a nonselective PPAR agonist, and the restoration of ovulation in CC-resistant PCOS patients by bezafibrate might be due to the action of decreasing insulin levels via the PPARG pathway. However, it takes at least 3 mo to reduce the resistance by using insulin-sensitizing drugs [57, 58] , while it took only 2 wk of bezafibrate treatment to obtain preovulatory mature follicles in our study [27] . Although there is a possibility that bezafibrate improved ovulatory function through the reduction of of peripheral insulin resistance, results in previous [27] and present studies suggest that bezafibrate, more importantly, directly affects follicle development and steroidogenesis. In fact, several studies report that insulin-sensitizing drugs have direct effects on ovarian cells, such as thecal and granulosa cells [62] [63] [64] . For example, the PPARG agonists metformin and troglitazone suppress androgen synthesis in human and porcine thecal cells [62, 63] . Most of these studies focused mainly on the effects of insulin-sensitizing drugs on steroidogenesis in ovarian cells. In this study, although bezafibrate treatment did not affect basal E2 production, it rescued the inhibition by TNF of FSH-induced E2 production (Fig. 3) . We found that bezafibrate treatment increased progesterone production in KGN cells, a human granulosa tumor cell line (our unpublished data). So far, no reports have shown that bezafibrate directly affects steroidogenesis in a variety of cells. Several reports have described that PPARG agonists increase progesterone production in porcine thecal cells [65] and rat and ovine granulosa cells [30, 66] . We showed that PPARG was expressed in mouse preantral follicles (Fig. 4) and that GW1929, a selective PPARG agonist, improved the inhibition by TNF of FSH-induced E2 production, similar to bezafibrate (Fig. 5) . Moreover, GW9662, a selective PPARG antagonist, abolished the restorative effects of bezafibrate on the inhibition by TNF of FSH-induced E2 production (Fig. 6) . Therefore, bezafibrate may stimulate steroidogenesis in the follicle through the PPARG-stimulating pathway.
We also found that bezafibrate improved the inhibition by TNF of FSH-induced follicle development: follicle survival and antral-like cavity formation (Fig. 3) . The mechanisms by which follicle survival and antrum formation were restored by bezafibrate remain unknown. Although we did not examine the apoptosis of follicles treated with TNF, many reports suggest that TNF is involved in the apoptosis of follicular cells, which indicates follicle atresia [21, 22] . There are no reports stating whether bezafibrate prevents apoptosis in ovarian cells. In this study, we showed that GW1929, like bezafibrate, improved the inhibition by TNF of FSH-induced follicle survival and antrum formation (Fig. 5) . Moreover, GW9662, a selective PPARG antagonist, abrogated the restorative effects of bezafibrate on the inhibition by TNF of FSH-induced follicle survival and antrum formation (Fig. 6) . Therefore, PPARG stimulation might be involved in follicle survival and antrum formation. By studying the ovarian-specific disruption of the PPARG model using Cre/loxP technology, Cui et al. [67] reported that PPARG plays an important role in normal ovarian function [67] . Butts et al. [68] reported that transfection of PPARG increased expression of BCL2 mRNA and protein, an apoptotic factor; however, administration of troglitazone, a PPARG agonist, to cultured rat granulosa cells decreased levels of BCL2 mRNA and stimulated apoptosis [69] . Moreover, Froment et al. [66] reported that PPARG decreased sheep granulosa cell proliferation. Thus, there are conflicting reports about the apoptotic and antiapoptotic effects of PPARG. Further examination of the role of PPARG in follicle development is needed.
In conclusion, results of this study suggest that bezafibrate improves the inhibition by TNF of FSH-induced follicle development and steroidogenesis through the PPARG-stimulating pathway. This study is a first step toward investigating the role of adipocytokines in follicle development and steroidogenesis by using an in vitro follicle culture system.
